NCT06539624招募中不适用
A Multicenter, Non-randomized, Open-label, Dose-finding Study to Evaluate the Safety and Preliminary Efficacy of Gene Therapy With EXG110 in Subjects With Fabry Disease
The Children's Hospital of Zhejiang University School of Medicine2 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2024年10月16日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 12
- 试验地点
- 2
- 主要终点
- Incidence and severity of adverse events
研究概览
简要总结
Objective: To explore the safety and tolerability of different doses of EXG110 with Fabre disease
详细描述
An open-label, multicenter, single-arm, non-randomized, dose-escalation, and recommended dose-extension clinical design was used to evaluate the safety and efficacy of a single intravenous administration of different doses of EXG110 in patients
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 7 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •At the time of signing the informed consent, age ≥7, male or female
- •Clinical symptoms (at least one Fabry disease related symptom) and genetic diagnosis of Fabry disease,
- •Prior or no prior ERT treatment
- •Have renal or cardiac involvement (adults only)
- •All subjects of reproductive age voluntarily took effective contraception and prohibited sperm donation from entering the screening period until 52 weeks after dosing (main study period)
- •The subjects voluntarily participate and are fully informed, fully understand the research, can comply with the requirements of the research protocol, and are willing to complete the research as planned, and voluntarily provide biological samples for testing according to the requirements of the protocol
排除标准
- •Screening period laboratory test results: a) aspartate aminotransferase or alanine aminotransferase > 1.5× upper limit of normal (ULN);b) Total bilirubin > 1.5× upper limit of normal (ULN);c) Alkaline phosphatase > 2× upper limit of normal (ULN);d) Albumin < lower limit of normal (LLN)
- •There was a clinically significant increase in AFP during the screening period
- •Serum virology test: a) Hepatitis B: Hepatitis B virus surface antigen (HBsAg) positive, and hepatitis B virus-deoxyribonucleic acid (HBV-DNA) higher than the upper limit of normal detection;b) Hepatitis C: if the hepatitis C virus (HCV) antibody is positive, and the hepatitis C virus-ribonucleic acid (HCV-RNA) is higher than the upper limit of normal test value;c) Syphilis: positive for syphilis screening (Tp-Ab) and positive for syphile-specific antibodies;d) HIV: Known human immunodeficiency virus (HIV) positive history or HIV screening positive
- •AVT917 (>1:50), anti-AGA antibody positive(>1:2560)
- •C3 lower than the normal range, C5b-9 higher than the normal range, anti-AVT917 IgM positive
- •Current or have a history of serious cardiovascular disease and surgical history
- •Current underlying liver disease or history of liver disease, as assessed by the investigator, that may affect the safety assessment of the drug
- •Renal disease in adult and the slope of kidney >5 mL/min/1.73m²/year
- •Subjects with poorly controlled diabetes after drug treatment (e.g., HbA1c≥8%);
- •Acute/chronic infection or other chronic disease that the investigator determines will increase the risk of participants participating in the study
- •Patients with a history of malignant tumor or currently suffering from any malignant tumor (except for the following tumor diseases: skin basal cell carcinoma, cervical carcinoma in situ, breast carcinoma in situ, skin squamous cell carcinoma has been controlled after treatment);
- •Have malignancy cancer
- •Patients with active autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, immune vasculitis, inflammatory bowel disease, etc.);
- •known history of allergy to the components of the investigational products
- •Patients with a history of drug use or drug abuse or alcoholism
- •Use of systemic (intravenous or oral) immunomodulators within the past 6 months or currently
- •Initiation of treatment with blood pressure lowering drugs that affect proteinuria levels (such as angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, or angiotensin-receptor/enkephalin inhibitors) within 4 weeks prior to screening, or changes in the therapeutic dose of these drugs within 4 weeks prior to screening;
- •Has received, or is currently receiving, a clinical trial of another investigational drug/medical device or treatment (other than vitamins and minerals) within 3 months prior to signing the informed consent (or within 5 half-lives of the investigational drug, whichever is longer)
- •Previous treatment with gene therapy products
- •Those who had received live attenuated vaccine/vaccine within 12 weeks prior to screening or planned to receive it during the study
- •Other clinical conditions that the investigators felt needed to be ruled out
结局指标
主要结局
Incidence and severity of adverse events
时间窗: 52 weeks following EXG110 administration
Safety and tolerability of EXG110 following a single IV dose, as assessed by incidence and severity of adverse events, serious adverse events and dose limiting toxicities, including clinically significant changes from baseline to scheduled time points in safety parameters
次要结局
- NYHA cardiac function grade changed from baseline;(52 weeks following EXG110 administration)
- Changed from baseline: region and area in mm^2 of skin angiokeratoma The number of Gb3 deposition in skin biopsy under the microscope(52 weeks following EXG110 administration)
- Change from baseline in serum AGA activity(52 weeks following EXG110 administration)
- Change from baseline serum lysoGb3(52 weeks following EXG110 administration)
- eGFR change from baseline in mL/min/(1.73m^2);(52 weeks following EXG110 administration)
研究者
Mao Jianhua
Vice President of the hospital
The Children's Hospital of Zhejiang University School of Medicine
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Study of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD)Macular DegenerationNCT00109499GenVec
已完成
1 期
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent MalignanciesMetastatic Castration-resistant Prostrate CancerMetastatic MelanomaRenal Cell CarcinomaNon-small Cell Lung CancerNCT00730639Bristol-Myers Squibb395
已完成
2 期
A Study of MDX-1100 in Subjects With Active Ulcerative ColitisUlcerative ColitisNCT00656890Bristol-Myers Squibb110
进行中（未招募）
3 期
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)NASH/MASHNAFLD/MASLDNCT06161571Akero Therapeutics, Inc700
终止
1 期
A Study of HFB301001 in Adult Patients With Advanced Solid TumorsSoft Tissue SarcomaUterine CarcinosarcomaHead and Neck Squamous Cell CarcinomaHepatocellular CarcinomaMelanomaRenal Cell CarcinomaNCT05229601HiFiBiO Therapeutics31